Cargando…

Chronic Medication Burden and Complexity for US Patients with Type 2 Diabetes Treated with Glucose-Lowering Agents

INTRODUCTION: Most adults with type 2 diabetes (T2D) have several chronic conditions treated with complex regimens and multiple medications. The burden and complexity of multiple medication use are associated with worse patient outcomes, including reduced adherence and increased costs, hospitalizati...

Descripción completa

Detalles Bibliográficos
Autores principales:	Boye, Kristina S., Mody, Reema, Lage, Maureen J., Douglas, Steven, Patel, Hiren
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7324456/ https://www.ncbi.nlm.nih.gov/pubmed/32447737 http://dx.doi.org/10.1007/s13300-020-00838-6

Ejemplares similares

Time to Failure on Oral Glucose-Lowering Agents for Patients with Type 2 Diabetes: A Retrospective Cohort Study
por: Boye, Kristina S., et al.
Publicado: (2021)

Clinical and economic outcomes among injection-naïve patients with type 2 diabetes initiating dulaglutide compared with basal insulin in a US real-world setting: the DISPEL Study
por: Mody, Reema, et al.
Publicado: (2019)

Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study
por: Boye, Kristina, et al.
Publicado: (2020)

Glucagon-Like Peptide-1 Receptor Agonist Use and Renal Impairment: A Retrospective Analysis of an Electronic Health Records Database in the U.S. Population
por: Boye, Kristina S., et al.
Publicado: (2018)

Real-World Treatment Patterns of Glucose-Lowering Agents Among Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease or At Risk for Cardiovascular Disease: An Observational, Cross-Sectional, Retrospective Study
por: Nair, Radhika, et al.
Publicado: (2022)

The Association Between HbA1c and 1-Year Diabetes-Related Medical Costs: A Retrospective Claims Database Analysis
por: Boye, Kristina S., et al.
Publicado: (2022)

Development of a patient-reported outcome (PRO) measure to assess patient perceptions of simplicity and complexity of treatment for type 2 diabetes
por: Stewart, Katie D., et al.
Publicado: (2023)

Generalizability of glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials to the overall type 2 diabetes population in the United States
por: Boye, Kristina S., et al.
Publicado: (2019)

Trends in HbA1c and Body Mass Index Among Individuals with Type 2 Diabetes: Evidence from a US Database 2012–2019
por: Boye, Kristina S., et al.
Publicado: (2021)

Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12‐month follow‐up in a real‐world setting in the United States
por: Mody, Reema, et al.
Publicado: (2019)

Effects of glucose-lowering agents on cardiorespiratory fitness
por: Hamasaki, Hidetaka
Publicado: (2018)

Effects of glucose-lowering agents on ischemic stroke
por: Avgerinos, Konstantinos, et al.
Publicado: (2017)

Use of Glucose-Lowering Agents in Diabetes and CKD
por: Alicic, Radica Z., et al.
Publicado: (2022)

The Association Between Sustained HbA1c Control and Long-Term Complications Among Individuals with Type 2 Diabetes: A Retrospective Study
por: Boye, Kristina S., et al.
Publicado: (2022)

Adherence to Basal Insulin Therapy Among People with Type 2 Diabetes: A Retrospective Cohort Study of Costs and Patient Outcomes
por: Perez-Nieves, Magaly, et al.
Publicado: (2018)

Real-World Effectiveness of Dulaglutide in Patients with Type 2 Diabetes Mellitus: A Literature Review
por: Robinson, Susan, et al.
Publicado: (2020)

Cardiac gene therapy treats diabetic cardiomyopathy and lowers blood glucose
por: Li, Jing, et al.
Publicado: (2023)

Diabetes, bone and glucose-lowering agents: basic biology
por: Lecka-Czernik, Beata
Publicado: (2017)

Efficacy of tirzepatide 5, 10 and 15 mg versus semaglutide 2 mg in patients with type 2 diabetes: An adjusted indirect treatment comparison
por: Vadher, Karan, et al.
Publicado: (2022)

Exit Interviews Examining the Patient Experience in Clinical Trials of Tirzepatide for Treatment of Type 2 Diabetes
por: Matza, Louis S., et al.
Publicado: (2022)

Associations between adherence and outcomes among older, type 2 diabetes patients: evidence from a Medicare Supplemental database
por: Boye, Kristina Secnik, et al.
Publicado: (2016)

The Association Between Obesity and the 5-Year Prevalence of Morbidity and Mortality Among Adults with Type 2 Diabetes
por: Boye, Kristina S., et al.
Publicado: (2023)

Meta-Analysis: Association Between Hypoglycemia and Serious Adverse Events in Older Patients Treated With Glucose-Lowering Agents
por: Mattishent, Katharina, et al.
Publicado: (2021)

Glucose-Lowering Medication Use in CKD: Analysis of US Medicare Beneficiaries Between 2007 and 2016
por: Zhao, Julie Z., et al.
Publicado: (2020)

Adherence and persistence among patients with type 2 diabetes initiating dulaglutide compared with semaglutide and exenatide BCise: 6‐month follow‐up from US real‐world data
por: Mody, Reema, et al.
Publicado: (2020)

Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents
por: Infante, Marco, et al.
Publicado: (2022)

Effects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites
por: Wang, Dongmei, et al.
Publicado: (2022)

Levothyroxine Treatment of Pregnant Women with Hypothyroidism: Retrospective Analysis of a US Claims Database
por: Lage, Maureen J., et al.
Publicado: (2020)

The Association Between Adherence to Insulin Therapy and Health Care Costs for Adults with Type 2 Diabetes: Evidence from a U.S. Retrospective Claims Database
por: Eby, Elizabeth L., et al.
Publicado: (2020)

Burden of disease associated with lower levels of income among US adults aged 65 and older
por: Lubetkin, Erica I, et al.
Publicado: (2017)

Metformin acutely lowers blood glucose levels by inhibition of intestinal glucose transport
por: Horakova, Olga, et al.
Publicado: (2019)

Bromocriptine as a Potential Glucose-lowering Agent for the Treatment of Prolactinoma with Type 2 Diabetes
por: Oshige, Tamami, et al.
Publicado: (2019)

Sodium-glucose Cotransporter-2 Inhibitors in Combination with Other Glucose-lowering Agents for the Treatment of Type 2 Diabetes Mellitus
por: Kalra, Sanjay, et al.
Publicado: (2018)

MON-LB099 The Association between Switching from Synthroid(®) and Clinical Outcomes: Retrospective Analysis of a US Database
por: Espillat, Ramon, et al.
Publicado: (2019)

Burden and management of chronic kidney disease in Japan: systematic review of the literature
por: Travers, Karin, et al.
Publicado: (2013)

Role of Glucose-Lowering Medications in Erectile Dysfunction
por: Cignarelli, Angelo, et al.
Publicado: (2021)

The role of glucose lowering agents on restenosis after percutaneous coronary intervention in patients with diabetes mellitus
por: Lexis, Chris PH, et al.
Publicado: (2009)

Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors
por: Scheen, André J.
Publicado: (2018)

Cost per Patient Achieving Treatment Targets and Number Needed to Treat with Tirzepatide Versus Semaglutide 1 mg in Patients with Type 2 Diabetes in the United States
por: Mody, Reema R., et al.
Publicado: (2023)

Current approaches toward the removal of methylene blue dye from synthetic textile effluent using bacterial treated agricultural waste absorbent through statistical design
por: Patel, Binal Y., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_kfl9n298sk8cecnqdpseral7oc